Adaptimmune Reports First Quarter Financial Results and Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- S&P 500, Nasdaq set for lower open as AI stocks slide on debt concerns
- U.S. producer prices rise by 1.3% month-on-month in September
- Oil prices slips as US weighs easing sanctions on 'shadow fleet'
- UBS now expects a third Fed rate hike after hot September inflation print
- Walmart stock: Deutsche Bank gets bullish amid pricing tailwinds
- Nebius shares sink on CoreWeave's bond yield spike and insider sales
- IonQ prices $2 billion equity offering at $40 per share
- Rocket Lab delays Neutron rocket debut to 2027
- Bloom Energy stock falls as inflation data pressures markets
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
Adaptimmune Therapeutics (ADAP) Tops Q1 EPS by 19c
May 12, 2023 7:32 AM EDTAdaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of $0.00, $0.19 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $47.6 million versus the consensus estimate of $4.9 million.
For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.
... More


